U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on ...

Eli Lilly and Company (LLY) said on Monday that the highest approved doses of its weight-loss drug Zepbound will soon be ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

STORY: Eli Lilly said Monday it will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were ...

INDIANAPOLIS, Ind. - Eli Lilly and Company, a major pharmaceutical company, announced on Monday that its weight-loss drug, ...

Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...